Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AmVac, a Switzerland-based biopharmaceutical company, has been granted a European patent (EP 1851 239 B1) for its platform technology for Sendai its subsidiary company AmVac Research.
Subscribe to our email newsletter
AmVac said that the novel technology, used for producing vaccines and has been developed at the research site in Martinsried near Munich, Germany, is completely covered by the granted patent.
Reeportedly, the patent was granted effective of January 21, 2009 in 29 EPC (European Patent Convention) countries. A communication was issued by the European Patent Office that no opposition has been filed against said patent within the statutory nine months term for doing so.
The patent for the Sendai platform technology broadly covers its use for any recombinant, replication deficient negative-strand RNA virus with a mutation in the so-called P-gene. This broad protection covers all development activities in relation to the Sendai platform technology for developing vaccines against a number of infectious diseases.
AmVac has filed the entire patent family beyond the borders of the EU in the other countries Australia, Brazil, Canada, China, Hong-Kong, Eurasia, Israel, India, Japan, Korea, Mexico, Singapore, The United States, and South Africa. AmVac has already been successful in Mexico and South Africa.